Arax Advisory Partners’s UroGen Pharma URGN Stock Holding History

Arax Advisory Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$432K	Buy	+11,739	New	+$318K	﹤0.01%	1725
2026 Q1	–	Sell	-14	Closed	-$328	–	4346
2025 Q4	$328	Sell	14 -12,365	-100%	-$268K	﹤0.01%	3661
2025 Q3	$247K	Buy	+12,379	New	+$222K	﹤0.01%	1167
2024 Q4	–	Sell	-56	Closed	-$712	–	2752
2024 Q3	$712	Hold	56	–	–	﹤0.01%	2343
2024 Q2	$940	Buy	+56	New	+$797	﹤0.01%	2188

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Arax Advisory Partners's URGN Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in UroGen Pharma (URGN) in Q2 2026: 11,739 shares worth $432K. The stake represents ﹤0.01% of the portfolio and ranks #1725 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in URGN as recently as Q4 2025.

Arax Advisory Partners first reported a position in URGN in Q2 2024 and has held it in 5 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Arax Advisory Partners held 11,739 shares of UroGen Pharma worth $432K as of Q2 2026.
UroGen Pharma was a new Arax Advisory Partners position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1725 holding.
Arax Advisory Partners first reported a position in UroGen Pharma in Q2 2024 and has held it in 5 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.